Systematic review of molecular biomarkers predictive of resistance to CDK4/6 inhibition in metastatic breast cancer
US Asghar, R Kanani, R Roylance… - JCO precision …, 2022 - ascopubs.org
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have revolutionized the treatment of
hormone-positive metastatic breast cancers (mBCs). They are currently established as …
hormone-positive metastatic breast cancers (mBCs). They are currently established as …
[HTML][HTML] Latest overview of the cyclin-dependent kinases 4/6 inhibitors in breast cancer: the past, the present and the future
X Chen, D Xu, X Li, J Zhang, W Xu, J Hou… - Journal of …, 2019 - ncbi.nlm.nih.gov
Endocrine resistance in hormone receptor positive breast cancer patients urges us to
develop novel approaches such as inhibitors of the cyclin-dependent kinases (CDK) 4/6 to …
develop novel approaches such as inhibitors of the cyclin-dependent kinases (CDK) 4/6 to …
Vitamin D supplementation to the older adult population in Germany has the cost‐saving potential of preventing almost 30 000 cancer deaths per year
T Niedermaier, T Gredner, S Kuznia… - Molecular …, 2021 - Wiley Online Library
Recent meta‐analyses of randomized controlled trials (RCTs) have demonstrated significant
reduction in cancer mortality by vitamin D supplementation. We estimated costs and savings …
reduction in cancer mortality by vitamin D supplementation. We estimated costs and savings …
Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
D Ding, H Hu, S Li, Y Zhu, Y Shi, M Liao, J Liu… - Journal of the National …, 2021 - jnccn.org
Background: In the CASPIAN trial, durvalumab 1 chemotherapy demonstrated significant
improvements in overall survival compared with chemotherapy alone in patients with …
improvements in overall survival compared with chemotherapy alone in patients with …
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 …
L She, H Hu, M Liao, X Xia, Y Shi, L Yao, D Ding, Y Zhu… - Lung Cancer, 2019 - Elsevier
Objective The purpose of this study was to estimate the cost-effectiveness analysis of
pembrolizumab versus chemotherapy as first-line treatment in locally advance or metastatic …
pembrolizumab versus chemotherapy as first-line treatment in locally advance or metastatic …
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
J Yang, J Han, Y Zhang, M Muhetaer… - Frontiers in …, 2022 - frontiersin.org
Background: The DESTINY-Breast03 clinical trial demonstrated that trastuzumab deruxtecan
(T-DXd) outperformed trastuzumab emtansine (T-DM1) in progression-free survival (PFS) in …
(T-DXd) outperformed trastuzumab emtansine (T-DM1) in progression-free survival (PFS) in …
Systematic review of the cost effectiveness of breast cancer prevention, screening, and treatment interventions
J Jayasekera, JS Mandelblatt - Journal of Clinical Oncology, 2020 - ascopubs.org
Methods This study used study-level results and was exempt from institutional review board
approval at Georgetown University. The review followed the guidelines included in the …
approval at Georgetown University. The review followed the guidelines included in the …
[HTML][HTML] CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta …
N Zeng, J Han, Z Liu, J He, K Tian, N Chen - Cancers, 2023 - mdpi.com
Simple Summary Recently updated results of clinical studies have confirmed that cyclin-
dependent kinase 4/6 (CDK4/6) inhibitors such as palbociclib (Palbo), ribociclib (Ribo), and …
dependent kinase 4/6 (CDK4/6) inhibitors such as palbociclib (Palbo), ribociclib (Ribo), and …
Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer
H Hu, L She, M Liao, Y Shi, L Yao, D Ding, Y Zhu… - Frontiers in …, 2020 - frontiersin.org
Background: The CheckMate 227 trial has indicated that nivolumab plus ipilimumab
compared with chemotherapy significantly increases long-term survival in the first-line …
compared with chemotherapy significantly increases long-term survival in the first-line …
First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
Y Zhu, H Hu, D Ding, S Li, M Liao, Y Shi… - Cost Effectiveness and …, 2021 - Springer
Background The clinical trial of Keynote-604 showed that pembrolizumab plus
chemotherapy could generate clinical benefits for extensive-stage small-cell lung cancer …
chemotherapy could generate clinical benefits for extensive-stage small-cell lung cancer …